Status:
COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12470
Lead Sponsor:
Hanmi Pharmaceutical Company Limited
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to investigate safety, tolerability, pharmacokinetics (PK) ad pharmacodynamics (PD) of HM12470 after single injection in T1DM and T2DM patients.
Detailed Description
This study is designed to evaluate safety, tolerability, PK and PD of HM12470 after single administration in subjects with T1DM and T2DM. In some cohorts for this study, the safety, tolerability, PK a...
Eligibility Criteria
Inclusion
- Inclusion Criteria for T1DM:
- T2DM more than 12 monthM
- Age ≥18 and ≤70 years
- Body mass index between 18.0 and 35.0 kg/m2 inclusive.
- Considered generally healthy upon completion of medical history, physical examination and biochemical investigations as judged by the Investigator.
- Females must be non-pregnant and non-lactating, and either surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or post-menopausal for \>12 months. Males must be surgically sterile, abstinent or if engaged in sexual relations of child-bearing potential, the subject must be using an acceptable contraceptive method during and for during a period of 60 days after the last dose of Study Drug.
- Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject).
- Inclusion Criteria for T2DM:
- T1DM more than 12 monthM
- Age ≥18 and ≤70 years
- Body mass index between 18.0 and 30.0 kg/m2 inclusive.
- Considered generally healthy upon completion of medical history, physical examination and biochemical investigations as judged by the Investigator.
- Females must be non-pregnant and non-lactating, and either surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or post-menopausal for \>12 months. Males must be surgically sterile, abstinent or if engaged in sexual relations of child-bearing potential, the subject must be using an acceptable contraceptive method during and for during a period of 60 days after the last dose of Study Drug.
- Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject).
- Exclusion Criteria
- A subject who has proliferative retinopathy or maculopathy, severe gastroparesis, and/or severe neuropathy, in particular autonomic neuropathy, as judged by the Investigator
- Recurrent major hypoglycemia or hypoglycemic unawareness or recent ketoacidosis
- pregnant or lactating women
- participation in an investigational study within 30 days prior to dosing
- Clinically significant abnormal ECG at screening, as judged by the Investigator
Exclusion
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2017
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT02302443
Start Date
January 1 2015
End Date
May 1 2017
Last Update
November 8 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hanmi Pharmaceutical Company
Seoul, South Korea